Management wants to kill off dara – more than once
Chapter 5. This is the story about the founding of Genmab and the development of the company’s lead asset, oncology drug daratumumab. The fifth installment details how the drug only exists today because of a certain Dutch exec who puts up a fight when the rest of the management team tries to shelve the drug on more than one occasion.
BY LONNI LYNGE
It is not as if there has not been any setbacks in the history of Genmab. When the biotech company went public on October 18th 2000, the share price began trading at DKK 233. The following December the price had nose-dived to DKK 116 and in 2002 it nearly hit rock bottom at just over DKK 22.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
Med din prøveperiode får du:
Få fuld adgang til dig og dine kollegaer
Start et gratis virksomhedsprøveabonnementRelaterede artikler
Popping the cork
For abonnenter
”It’s a slam dunk”
For abonnenter
Management wants to kill off dara – more than once
For abonnenter
